Strengthening National Immunization Technical Advisory Groups in resource-limited settings: current and potential linkages with polio national certification committees

Health Research Policy and Systems
http://www.health-policy-systems.com/content
[Accessed 10 Oct 2020]

 

Content type: Research
Strengthening National Immunization Technical Advisory Groups in resource-limited settings: current and potential linkages with polio national certification committees
Authors: Sharon A. Greene, Blanche-Philomene Melanga Anya, Humayun Asghar, Irtaza A. Chaudhri, S. Deblina Datta, Morgane E. Donadel, Koffi Isidore Kouadio, Abigail M. Shefer and Kathleen F. Cavallaro
6 October 2020
Countries are transitioning assets and functions from polio eradication to integrated immunization and surveillance activities. We assessed the extent of linkages between and perceptions of National Immunization Technical Advisory Groups (NITAGs) and National Certification Committees (NCCs) for polio eradication to understand how linkages can be leveraged to improve efficiencies of these expert bodies.

Disability inclusion in humanitarian action

Humanitarian Exchange Magazine
Number 78, October 2020
https://odihpn.org/magazine/inclusion-of-persons-with-disabilities-in-humanitarian-action-what-now/

Disability inclusion in humanitarian action
by HPN October 2020
The theme of this edition of Humanitarian Exchange, co-edited with Sherin Alsheikh Ahmed from Islamic Relief Worldwide, is disability inclusion in humanitarian action. Persons with disabilities are not only disproportionately impacted by conflicts, disasters and other emergencies, but also face barriers to accessing humanitarian assistance. At the same time, global commitments and standards and the IASC Guidelines on the inclusion of persons with disabilities in humanitarian action all emphasise how persons with disabilities are also active agents of change. Disability and age-focused organisations have led on testing and demonstrating how inclusion can be done better. Yet despite this progress, challenges to effective inclusion remain.

As Kirstin Lange notes in the lead article, chief among these challenges is humanitarian agencies’ lack of engagement with organisations of persons with disabilities. Simione Bula, Elizabeth Morgan and Teresa Thomson look at disability inclusion in humanitarian response in the Pacific, and Kathy Al Jubeh and Alradi Abdalla argue for a ‘participation revolution’, building on learning from the gender movement. Tchaurea Fleury and Sulayman AbdulMumuni Ujah outline how the Bridge Article 11 training initiative is encouraging constructive exchange between humanitarian and disability actors. The lack of good, disaggregated data is highlighted by Sarah Collinson; Frances Hill, Jim Cranshaw and Carys Hughes emphasise the need for training resources in local languages and accessible formats; and Sophie Van Eetvelt and colleagues report on a review of the evidence on inclusion of people with disabilities and older people.

Rebecca Molyneux and co-authors analyse the findings of a review of a DFID programme in north-east Nigeria, while Carolin Funke highlights the importance of strategic partnerships between disability-focused organisations, drawing on her research in Cox’s Bazar. Sherin Alsheikh Ahmed describes Islamic Relief Worldwide’s approach to mainstreaming protection and inclusion, while Pauline Thivillier and Valentina Shafina outline IRC’s Client Responsive Programming. The edition ends with reflections by Mirela Turcanu and Yves Ngunzi Kahashi on CAFOD’s SADI approach.

COVID-19 and the Path to Immunity

JAMA
October 6, 2020, Vol 324, No. 13, Pages 1261-1362
https://jamanetwork.com/journals/jama/currentissue

 

Viewpoint
COVID-19 and the Path to Immunity
David S. Stephens, MD; M. Juliana McElrath, MD, PhD
free access has active quiz
JAMA. 2020;324(13):1279-1281. doi:10.1001/jama.2020.16656
This Viewpoint reviews what is known about acute and long-term B-cell, antibody, and T-cell responses to SARS-CoV-2 infection and explains how each are implicated in vaccine candidates likely to be effective and durably protective again COVID-19.

Emergency Use Authorizations During the COVID-19 PandemicLessons From Hydroxychloroquine for Vaccine Authorization and Approval

JAMA
October 6, 2020, Vol 324, No. 13, Pages 1261-1362
https://jamanetwork.com/journals/jama/currentissue

 

Viewpoint
Emergency Use Authorizations During the COVID-19 PandemicLessons From Hydroxychloroquine for Vaccine Authorization and Approval
Kyle Thomson, JD, MPH; Herschel Nachlis, PhD
free access has active quiz has multimedia has audio
JAMA. 2020;324(13):1282-1283. doi:10.1001/jama.2020.16253
This Viewpoint uses the FDA’s Emergency Use Authorization (EUA) of hydroxychloroquine for COVID-19 treatment to emphasize the costs of premature regulatory authorizations to public health and trust, and proposes the use of advisory committees, requirements for postmarketing surveillance, and adherence to standards of transparency for any future EUAs.

Regulatory Decision-making on COVID-19 Vaccines During a Public Health Emergency

JAMA
October 6, 2020, Vol 324, No. 13, Pages 1261-1362
https://jamanetwork.com/journals/jama/currentissue

 

Viewpoint
Regulatory Decision-making on COVID-19 Vaccines During a Public Health Emergency
Jerry Avorn, MD; Aaron Kesselheim, MD, JD, MPH
free access has active quiz has multimedia has audio
JAMA. 2020;324(13):1284-1285. doi:10.1001/jama.2020.17101
This Viewpoint reviews the enormous political and public pressures the FDA is likely to be under in fall 2020 to provide emergency authorization or approval of candidate COVID-19 vaccines, and urges adherence to existing science-based protocols for approval to ensure vaccine safety and acceptance and thus protect the public’s health.

Reassuring the Public and Clinical Community About the Scientific Review and Approval of a COVID-19 Vaccine

JAMA
October 6, 2020, Vol 324, No. 13, Pages 1261-1362
https://jamanetwork.com/journals/jama/currentissue

 

Editorial
Reassuring the Public and Clinical Community About the Scientific Review and Approval of a COVID-19 Vaccine
Howard Bauchner, MD; Preeti N. Malani, MD, MSJ; Joshua Sharfstein, MD
Public perception of the review of medications and vaccines for coronavirus disease 2019 (COVID-19) has become enmeshed in politics. The pressure on the US Food and Drug Administration (FDA) and Commissioner Stephen Hahn, MD, to approve the broad use of a COVID-19 vaccine in the coming months will be immense. However, a lack of clarity about the agency’s approach—coupled with a stream of announcements from various federal agencies and pharmaceutical companies—has led to confusion and concern. Greater clarity and transparency about the review process as well as the full engagement of the relevant federal advisory committees can inspire understanding and trust.

A flurry of recent statements has captured headlines. Commissioner Hahn indicated that the FDA is willing to use an Emergency Use Authorization (EUA) for vaccines before phase 3 trials are complete.1 An EUA provides a rapid approach to facilitate availability and use of biologics, drugs, vaccines, devices, and diagnostic tests (referred to as “medical countermeasures”) during a public health emergency.2 Some medical experts have suggested that this approach is inappropriate. On August 27, 2020, the US Centers for Disease Control and Prevention (CDC) instructed states to begin to prepare for distribution of a vaccine in the coming months.3 On September 3, the chief executive officer (CEO) of Pfizer announced that the company will have sufficient data to know if its vaccine is effective by the end of October and will consider filing for EUA.4,5 But on September 4, the White House chief advisor for the coronavirus vaccine development program, Operation Warp Speed, announced that it was “extremely unlikely but not impossible” that a vaccine could be available by the end of October.6

On September 8 the CEOs of 9 pharmaceutical companies released a joint pledge that they are committed to “developing and testing potential vaccines for COVID-19 in accordance with high ethical standards and sound scientific principles.”7 The pledge indicates that they would “only submit for approval or emergency use authorization after demonstrating safety and efficacy through a Phase 3 clinical study that is designed and conducted to meet requirements of expert regulatory authorities such as FDA.” The statement does not include any commitment or suggestion that the data underpinning their application be shared with any other group.8 These announcements have left some clinicians, public health officials, and members of the public bewildered about what is actually happening and concerned that vaccines will be made available before safety and effectiveness are fully established.

The goal of making available a safe and effective COVID-19 vaccine is widely seen as critical for ending the pandemic, and Operation Warp Speed has accelerated the development, testing, and eventual distribution of such a vaccine. However, recent polls of adults suggest that as few as 50% of US adults are committed to receiving a COVID-19 vaccine,9 and misinformation and conspiracy theories about a vaccine abound. Prematurely approving a vaccine could undermine COVID-19 vaccination efforts and erode confidence in vaccines more generally.

The path forward starts with support, not mistrust, of the career FDA scientists and officials with the expertise to determine whether emerging vaccine candidates are ready for use in specific populations. The director of the FDA center responsible for vaccine review, Peter Marks, MD, told the Washington Post that the COVID-19 vaccine will only be authorized or licensed when it meets the existing guidelines for safety and efficacy.10 This statement of agency policy is reassuring. Rather than prejudging any decision, and consistent with the scientific method, FDA staff should have the ability to evaluate the data from phase 3 trials and make the case for whether those trials establish safety and effectiveness. The staff scientists should then be able to recommend either an EUA or full licensure to provide access to a safe and effective vaccine as quickly as possible. If the recommendation is for an EUA, the staff scientists should explain why this path was taken and how this would not mean compromising on the answers to critical questions.

Beyond internal deliberations within the FDA, a thorough and transparent review process of data supporting vaccine approval is essential to building public confidence in a COVID-19 vaccine.

Important safeguards should be established to reassure the clinical community and the public about any vaccine approval. The FDA should explain the role of the data and safety monitoring boards (DSMBs) for the vaccine trials, the first “independent” group that reviews the data, and any correspondence between the DSMB and the project investigators should be shared with the public. Two additional groups have an important consultant responsibility to the government and the public: the FDA Vaccines and Related Biological Products Advisory Committee11,12 and the Advisory Committee on Immunization Practices (ACIP).13 These advisory groups are composed of medical, scientific, health policy, and public health experts who review data and develop recommendations for the use of vaccines.

The FDA should share all allowable and available data about a vaccine candidate with the FDA vaccine advisory committee and ACIP prior to making any decision about an EUA or approval. Typically, the FDA’s vaccine committee makes recommendations prior to agency action, and ACIP soon afterward. In this challenging situation, the FDA should seek the input of both committees prior to making a decision. An FDA decision consistent with the advice of these independent experts will then reassure the public. However, if the FDA goes in a different direction, the agency will need to explain the reasons well to avoid confusion and vaccine hesitancy. If either panel is excluded from reviewing data, the FDA may struggle to convince the public and clinical community about the strength of the evidence, and vaccine uptake may be adversely affected.

Some have expressed concern that political appointees in the executive branch may insist on an EUA for a vaccine over the recommendation of FDA career scientists. Such interference would both present a direct risk to the US public and cause incalculable damage to public trust in the federal government’s ability to make critical scientific decisions. The FDA should be clear at the time of the announcement of an EUA or approval of a vaccine if such an EUA or approval had been mandated by members of the executive branch against the advice of the agency scientists. In such a scenario, Congress should take action to protect the public.

A more nuanced issue is the potential effect of an EUA or approval on ongoing research. The agency should work with the National Institutes of Health (NIH) to develop a joint approach to support ongoing vaccine trials, including further research on the vaccines in question. It would be unfortunate for the FDA and NIH to present conflicting views of a vaccine, as happened with convalescent plasma for treatment of severe COVID-19.

This is a time of great societal upheaval, and the response to the pandemic has required difficult decisions. An effective COVID-19 vaccine, if widely available and with substantial uptake, will allow society over time to return to some semblance of normalcy. The FDA remains the agency to answer the core question of when vaccines are safe and effective for the US population. It also remains essential for the FDA to be fully informed by independent scientific experts, to promote trust and confidence on the path to ending the pandemic.

Vaccine Refusal and Measles Outbreaks in the US

JAMA
October 6, 2020, Vol 324, No. 13, Pages 1261-1362
https://jamanetwork.com/journals/jama/currentissue

 

Clinical Update
Vaccine Refusal and Measles Outbreaks in the US
Varun K. Phadke, MD; Robert A. Bednarczyk, MS, PhD; Saad B. Omer, MBBS, MPH, PhD
has audio
JAMA. 2020;324(13):1344-1345. doi:10.1001/jama.2020.14828
This JAMA Insights feature provides a narrative update of a 2016 systematic review documenting an association between vaccine refusal and measles epidemiology in the US, and reaffirms based on the new evidence that vaccine refusal remains a significant contributor to measles resurgence in the postelimination era.

School Closure During the Coronavirus Disease 2019 (COVID-19) PandemicAn Effective Intervention at the Global Level?

JAMA Pediatrics
October 2020, Vol 174, No. 10, Pages 919-1012
http://archpedi.jamanetwork.com/issue.aspx

 

Viewpoint
School Closure During the Coronavirus Disease 2019 (COVID-19) PandemicAn Effective Intervention at the Global Level?
Susanna Esposito, MD; Nicola Principi, MD
free access has active quiz
JAMA Pediatr. 2020;174(10):921-922. doi:10.1001/jamapediatrics.2020.1892
This Viewpoint discusses the effectiveness of school closure as a preventive measure during the coronavirus disease 2019 (COVID-19) pandemic.

Study Designs and Statistical Methods for Studies of Child and Adolescent Health Policies

JAMA Pediatrics
October 2020, Vol 174, No. 10, Pages 919-1012
http://archpedi.jamanetwork.com/issue.aspx

 

Impact of Policy on Children
Study Designs and Statistical Methods for Studies of Child and Adolescent Health Policies
Benjamin French, PhD; Elizabeth A. Stuart, PhD
JAMA Pediatr. 2020;174(10):925-927. doi:10.1001/jamapediatrics.2020.3408
This Viewpoint discusses selection of data and statistical methods that can be used to estimate policy effects using that data.
Rigorous empirical studies of the effect of a policy intervention seek to consider (or estimate) what outcomes are (or would be) with the policy compared with what outcomes are (or would be) without the policy. For example, consider whether decriminalization of adult marijuana use (medical or recreational) is associated with adolescent marijuana use.1 As detailed below, one can use data over time from states that did and did not decriminalize adult marijuana use and compare observed trends in adolescent marijuana use among states with the policy change to expected (or predicted) trends in marijuana use, had the policy change not occurred, to estimate the policy effect. Of note, the policy effect could also be estimated in settings in which there is not a comparison group, such as if marijuana were decriminalized nationwide. We focus on settings often referred to as group panel data, for which there are aggregate data available on groups of interest with outcomes measured over time both before and after the policy change and ideally with comparison groups that did not experience a policy change; individual-level data could also be available within the groups. The data in some cases correspond with full population data at each time point; in others, there might be repeated cross-sections of data, such as annual surveys of marijuana use among 10th graders. As long as the data can be thought of as representative of the unit under study, either data structure can be appropriate. We broadly consider the selection of data to examine (eg, the units to study, the time period to examine) as well as the statistical methods that can be used to estimate policy effects using that data.

Gene and Stem Cell Therapies for Fetal Care – A Review

JAMA Pediatrics
October 2020, Vol 174, No. 10, Pages 919-1012
http://archpedi.jamanetwork.com/issue.aspx

 

Review
Gene and Stem Cell Therapies for Fetal Care – A Review
Amy E. O’Connell, MD, PhD; Stephanie Guseh, MD; Larissa Lapteva, MD, MHS, MBA; et al.
JAMA Pediatr. 2020;174(10):985-991. doi:10.1001/jamapediatrics.2020.1519
Abstract
Importance  Gene and stem cell therapies have become viable therapeutic options for many postnatal disorders. For select conditions, prenatal application would provide improved outcomes. The fetal state allows for several theoretical advantages over postnatal therapy, including immune immaturity and cellular niche accessibility.
Observations  Advances in prenatal diagnostic accuracy and surgical precision, as well as improvements in stem cell and gene therapy methods, have made prenatal gene and stem cell therapy realistic. Studies in mouse models and early human trials demonstrate the feasibility of these approaches. Additional efforts are under way to streamline fetal applications of stem cell and gene therapy while carefully considering best ethical practice and following established regulatory pathways.
Conclusions and Relevance  Fetal stem cell and gene therapy bring important therapeutic opportunities for select disorders that present in the fetal and neonatal periods. While this field is in its infancy, these therapies are starting to be available clinically, and clinicians should be aware of their benefits and challenges.

Managing the spread of disease with mobile phone data

Journal of Development Economics
Volume 147 November 2020
https://www.sciencedirect.com/journal/journal-of-development-economics/vol/147/suppl/C

 

Research article Open access
Managing the spread of disease with mobile phone data
Sveta Milusheva
Article 102559
Abstract
While human mobility has important benefits for economic growth, it can generate negative externalities. This paper studies the effect of mobility on the spread of disease in a low-incidence setting when people do not internalize their risks to others. Using malaria as a case study and 15 billion mobile phone records across nine million SIM cards, this paper quantifies the relationship between travel and the spread of disease. The estimates indicate that an infected traveler contributes to 1.66 additional cases reported in the health facility at the traveler’s destination. This paper develops a simulation-based policy tool that uses mobile phone data to inform strategic targeting of travelers based on their origins and destinations. The simulations suggest that targeting informed by mobile phone data could reduce the caseload by 50 percent more than current strategies that rely only on previous incidence.

Lancet COVID-19 Commission Statement on the occasion of the 75th session of the UN General Assembly

The Lancet
Oct 10, 2020 Volume 396 Number 10257 p1045-1128
https://www.thelancet.com/journals/lancet/issue/current

 

Commission Statement
Lancet COVID-19 Commission Statement on the occasion of the 75th session of the UN General Assembly
The Lancet COVID-19 Commissioners, Task Force Chairs, and Commission Secretariat
[See COVID-19 above for detail]

Why Nature needs to cover politics now more than ever

Nature
Volume 586 Issue 7828, 8 October 2020
http://www.nature.com/nature/current_issue.html

 

Editorial | 06 October 2020
Why Nature needs to cover politics now more than ever
Science and politics are inseparable — and Nature will be publishing more politics news, comment and primary research in the coming weeks and months.
[Editor’s text bolding in red]

Since Nature’s earliest issues, we have been publishing news, commentary and primary research on science and politics. But why does a journal of science need to cover politics? It’s an important question that readers often ask.

This week, Nature reporters outline what the impact on science might be if Joe Biden wins the US presidential election on 3 November, and chronicle President Donald Trump’s troubled legacy for science. We plan to increase politics coverage from around the world, and to publish more primary research in political science and related fields.

Science and politics have always depended on each other. The decisions and actions of politicians affect research funding and research-policy priorities. At the same time, science and research inform and shape a spectrum of public policies, from environmental protection to data ethics. The actions of politicians affect the higher-education environment, too. They can ensure that academic freedom is upheld, and commit institutions to work harder to protect equality, diversity and inclusion, and to give more space to voices from previously marginalized communities. However, politicians also have the power to pass laws that do the opposite.

The coronavirus pandemic, which has taken more than one million lives so far, has propelled the science–politics relationship into the public arena as never before, and highlighted some serious problems. COVID-related research is being produced at a rate unprecedented for an infectious disease, and there is, rightly, intense worldwide interest in how political leaders are using science to guide their decisions — and how some are misunderstanding, misusing or suppressing it. And there is much interest in the fluctuating relationship between politicians and the scientists who governments consult or employ.

Scholarly autonomy under threat

Perhaps even more troubling are signs that politicians are pushing back against the principle of protecting scholarly autonomy, or academic freedom. This principle, which has existed for centuries — including in previous civilizations — sits at the heart of modern science.

 

Today, this principle is taken to mean that researchers who access public funding for their work can expect no — or very limited — interference from politicians in the conduct of their science, or in the eventual conclusions at which they arrive. And that, when politicians and officials seek advice or information from researchers, it is on the understanding that they do not get to dictate the answers. This is the basis for today’s covenant between science and politics, and it applies across a range of research, education, public-policy and regulatory domains.

It is not a perfect system by any means. Some research areas are more autonomous than others, and autonomy can never be a blank cheque: researchers must also be held accountable for their actions, and standards of quality and integrity must be upheld. But protection for autonomy is a long-standing benchmark, the standard to which experts and policymakers aspire. It requires a degree of trust between researcher and politician that each will keep to their word. And when this trust starts to ebb away, the system, too, begins to look vulnerable.

That trust is now under considerable pressure around the world. Cracks have been evident for years in the field of climate change, with a number of politicians ignoring or seeking to undermine the irrefutable evidence showing that humans are the cause. But this lack of trust can now also be seen in other public domains in which verifiable knowledge and research are needed for effective policy-making.

Last year, Brazil’s President Jair Bolsonaro sacked the head of the country’s National Institute for Space Research because the president refused to accept the agency’s reports that deforestation in the Amazon has accelerated during his tenure. In the same year, more than 100 economists wrote to India’s prime minister, Narendra Modi, urging an end to political influence over official statistics — especially economic data — in the country.

And just last week, in Japan, incoming Prime Minister Yoshihide Suga rejected the nomination of six academics, who have previously been critical of government science policy, to the Science Council of Japan. This is an independent organization meant to represent the voice of Japanese scientists. It is the first time that this has happened since prime ministers started approving nominations in 2004.

The pandemic, too, is uncovering examples of political interference in science. In June in the United Kingdom, the statistics regulator wrote to the government, highlighting repeated inaccuracies in its COVID-19 testing data, which the regulator says seem to be aimed at showing “the largest possible number of tests”.

The fields of public-health and infectious-disease research have revealed much about the effects of pandemics and how to curb them. This year, a large volume of work on COVID-19 has illuminated the behaviour of both the virus and the disease. Research has also revealed uncertainties, gaps and errors in our knowledge, as would be expected. But that doesn’t excuse the behaviour we are seeing from politicians around the world, exemplified by Trump’s notorious actions: a chaotic, often ill-informed response, with scientists being attacked and undermined.

The principle that the state will respect scholarly independence is one of the foundations underpinning modern research, and its erosion carries grave risks for standards of quality and integrity in research and policymaking. When politicians break that covenant, they endanger the health of people, the environment and societies.

This is why Nature’s news correspondents will redouble their efforts to watch and report on what is happening in politics and research worldwide. It is why authors of our expert commentaries will continue to assess and critique developments; and why the journal is looking to publish more primary research in political science.

And, in these editorial pages, we will continue to urge politicians to embrace the spirit of learning and collaboration, to value different perspectives, and to honour their commitment to scientific and scholarly autonomy.

The conventions that have guided the relationship between science and politics are under threat, and Nature cannot stand by in silence.

COVID-19 vaccines: how to ensure Africa has access

Nature Biotechnology
Volume 38 Issue 10, October 2020
https://www.nature.com/nbt/volumes/38/issues/10

 

SARS-CoV-2 detection
In this issue, several groups report their findings on the development of methods to detect SARS-CoV-2 in patients and in the community, and benchmark assays to detect SARS-CoV-2-specific antibodies.

The conventions that have guided the relationship between science and politics are under threat, and Nature cannot stand by in silence.

 

Comment | 06 October 2020
COVID-19 vaccines: how to ensure Africa has access
History must not repeat itself — global and continental cooperation are essential.
John N. Nkengasong, Nicaise Ndembi[…] & Tajudeen Raji

Artificial intelligence, drug repurposing and peer review

Nature Biotechnology
Volume 38 Issue 10, October 2020
https://www.nature.com/nbt/volumes/38/issues/10

 

Comment | 14 September 2020
Artificial intelligence, drug repurposing and peer review
Can traditional computational analysis and machine learning help compensate for inadequate peer review of drug-repurposing papers in the context of an infodemic?
Jeremy M. Levin, Tudor I. Oprea[…] & Alex Zhavoronkov

Pledging intellectual property for COVID-19

Nature Biotechnology
Volume 38 Issue 10, October 2020
https://www.nature.com/nbt/volumes/38/issues/10

 

Patents | 05 October 2020
Pledging intellectual property for COVID-19
Voluntary pledges to make intellectual property broadly available to address urgent public health crises can overcome administrative and legal hurdles faced by more elaborate legal arrangements such as patent pools and achieve greater acceptance than governmental compulsory licensing.
Jorge L. Contreras, Michael Eisen[…] & Frank Tietze

Epidemiological impact and cost-effectiveness of universal meningitis b vaccination among college students prior to college entry

PLoS One
http://www.plosone.org/

 

Research Article
Epidemiological impact and cost-effectiveness of universal meningitis b vaccination among college students prior to college entry
Grace S. Chung, David W. Hutton
Research Article | published 09 Oct 2020 PLOS ONE
https://doi.org/10.1371/journal.pone.0239926

Improving quality and use of routine health information system data in low- and middle-income countries: A scoping review

PLoS One
http://www.plosone.org/

 

Improving quality and use of routine health information system data in low- and middle-income countries: A scoping review
Seblewengel Lemma, Annika Janson, Lars-Åke Persson, Deepthi Wickremasinghe, Carina Källestål
Research Article | published 08 Oct 2020 PLOS ONE
https://doi.org/10.1371/journal.pone.0239683

COVID-SCORE: A global survey to assess public perceptions of government responses to COVID-19 (COVID-SCORE-10)

PLoS One
http://www.plosone.org/

 

COVID-SCORE: A global survey to assess public perceptions of government responses to COVID-19 (COVID-SCORE-10)
Jeffrey V. Lazarus, Scott Ratzan, Adam Palayew, Francesco C. Billari, Agnes Binagwaho, Spencer Kimball, Heidi J. Larson, Alessia Melegaro, Kenneth Rabin, Trenton M. White, Ayman El-Mohandes
Research Article | published 06 Oct 2020 PLOS ONE
https://doi.org/10.1371/journal.pone.0240011

Preparedness needs research: How fundamental science and international collaboration accelerated the response to COVID-19

PLoS Pathogens
http://journals.plos.org/plospathogens/
[Accessed 10 Oct 2020]

 

Review
Preparedness needs research: How fundamental science and international collaboration accelerated the response to COVID-19
Cormac M. Kinsella, Pauline Dianne Santos, Ignacio Postigo-Hidalgo, Alba Folgueiras-González, Tim Casper Passchier, Kevin P. Szillat, Joyce Odeke Akello, Beatriz Álvarez-Rodríguez, Joan Martí-Carreras
| published 09 Oct 2020 PLOS Pathogens
https://doi.org/10.1371/journal.ppat.1008902
Abstract
The first cluster of patients suffering from coronavirus disease 2019 (COVID-19) was identified on December 21, 2019, and as of July 29, 2020, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections have been linked with 664,333 deaths and number at least 16,932,996 worldwide. Unprecedented in global societal impact, the COVID-19 pandemic has tested local, national, and international preparedness for viral outbreaks to the limits. Just as it will be vital to identify missed opportunities and improve contingency planning for future outbreaks, we must also highlight key successes and build on them. Concomitant to the emergence of a novel viral disease, there is a ‘research and development gap’ that poses a threat to the overall pace and quality of outbreak response during its most crucial early phase. Here, we outline key components of an adequate research response to novel viral outbreaks using the example of SARS-CoV-2. We highlight the exceptional recent progress made in fundamental science, resulting in the fastest scientific response to a major infectious disease outbreak or pandemic. We underline the vital role of the international research community, from the implementation of diagnostics and contact tracing procedures to the collective search for vaccines and antiviral therapies, sustained by unique information sharing efforts.

Seroprevalence of SARS-CoV-2 IgM and IgG antibodies in an asymptomatic population in Sergipe, Brazil

Revista Panamericana de Salud Pública/Pan American Journal of Public Health (RPSP/PAJPH)
https://www.paho.org/journal/en

 

6 Oct 2020
Seroprevalence of SARS-CoV-2 IgM and IgG antibodies in an asymptomatic population in Sergipe, Brazil
Original research | English |
Rojas-Cortés
Abstract
Objective.
To assess all the incidents of substandard, falsified and unregistered medicines in 2017 and 2018 in Latin America, determining the types of products affected, stages of the supply chain in which incidents were detected, quality deviations identified in tested samples, and regulatory measures taken by authorities.
Methods.
A comprehensive search of the websites of the Latin American national regulatory authorities was conducted, identifying all eligible incidents during 2017-2018. Standardized values were collected from each incident for pre-determined variables: country, year, type of incident, therapeutic group, supply chain, regulatory measures and laboratory data.
Results.
A total of 596 incidents in 13 countries were included (236 substandard, 239 falsified, 116 unregistered and 5 stolen). The therapeutic categories with the highest incidents were: anti-infectives, medicines for pain/palliative care, hormones/contraceptives, medicines for the respiratory tract, and medicines for mental/behavioural disorders. The most common places where incidents were detected were commercial establishments, pharmacies, health services and manufacturers. The most recurrent quality deviations were failure in parameters (appearance or physicochemical), incorrect labelling, different quantity of active pharmaceutical ingredient, presence of unknown particles, and microbiological contamination. The most frequent regulatory measures identified were alerts, withdrawals, seizures, and prohibition of marketing/distribution/use.
Conclusions.
In Latin America, substandard, falsified and unregistered medicines persist as a highly prevalent problem. An advanced degree of regulatory development in countries is associated with higher incident detection/reporting rates and a more comprehensive set of measures. The pharmaceutical supply chain is more vulnerable in its final node. Quality deviations identified in tested samples pose serious risks to public health.

A call to test new vaccines head to head, in monkeys

Science
09 October 2020 Vol 370, Issue 6513
http://www.sciencemag.org/current.dtl

 

In Depth
A call to test new vaccines head to head, in monkeys
By Jon Cohen
Science09 Oct 2020 : 154-155
Proposed comparison study could clarify safety and which vaccines work best.
Summary
Primate researchers in the United States have banded together in a push for an ambitious monkey study that would do head-to-head comparisons of the leading COVID-19 vaccine candidates. Although 10 candidates are already undergoing large-scale tests in people, proponents of the monkey plan say those clinical trials may not deliver the comprehensive data needed to choose the safest and most effective vaccines. The comparison trial in monkeys, in contrast, could shed light in a matter of weeks on how the candidates stack up on measures including potential side effects, the strength of immune responses they trigger, and how well they protect against infection and disease.

Sweden’s gamble

Science
09 October 2020 Vol 370, Issue 6513
http://www.sciencemag.org/current.dtl

 

Feature
Sweden’s gamble
By Gretchen Vogel
Science09 Oct 2020 : 159-163
The country’s pandemic policies came at a high price—and created painful rifts in its scientific community.
Summary
Sweden’s government is known for keeping schools and stores open despite the COVID-19 pandemic. But there are other striking differences in the country’s approach: Authorities actively discourage people from wearing face masks, and there has been very limited testing or contact tracing. Within Sweden’s scientific and medical community, a debate about the strategy has simmered and frequently boiled over. A group of scientists known as “the 22” has called for tougher measures since April, when it published a blistering critique of the country’s public health authority. The group, which has grown to include 50 scientists, now calls itself the Vetenskapsforum COVID-19 (Science Forum COVID-19). It says the price for Sweden’s laissez-faire approach has been too high. (The country’s cumulative COVID-19 death rate so far rivals that of the United States.) And although infections waned over the summer, cases are rising again. But the group’s criticism has not been welcomed. Some critics have been publicly reprimanded, and some have decided to leave the country.

Potential impact of tuberculosis vaccines in China, South Africa, and India

Science Translational Medicine
07 October 2020 Vol 12, Issue 564
https://stm.sciencemag.org/

 

Research Articles
Potential impact of tuberculosis vaccines in China, South Africa, and India
By Rebecca C. Harris, Tom Sumner, Gwenan M. Knight, Hui Zhang, Richard G. White
Science Translational Medicine07 Oct 2020
Tuberculosis vaccines should aim to protect infected populations against disease, but other vaccine types may be of use in high-transmission settings.
Inferring TB vaccine impact
There are multiple tuberculosis vaccines in development, although which vaccines are the best candidates to move forward is a matter of debate. Harris et al. used transmission models calibrated to age-specific demographic and epidemiological data from China, South Africa, and India to investigate the potential long-term impact of tuberculosis vaccines with different features, including results from recent clinical trials. They estimated that vaccines preventing disease, rather than infection per se, would have the greatest impact in these countries with high tuberculosis burdens. Their findings may aid prioritization and future trial planning of tuberculosis vaccines currently in development.
Abstract
More effective tuberculosis vaccines are needed to help reach World Health Organization tuberculosis elimination goals. Insufficient evidence exists on the potential impact of future tuberculosis vaccines with varying characteristics and in different epidemiological settings. To inform vaccine development decision making, we modeled the impact of hypothetical tuberculosis vaccines in three high-burden countries. We calibrated Mycobacterium tuberculosis (M.tb) transmission models to age-stratified demographic and epidemiological data from China, South Africa, and India. We varied vaccine efficacy to prevent infection or disease, effective in persons M.tb uninfected or infected, and duration of protection. We modeled routine early-adolescent vaccination and 10-yearly mass campaigns from 2025. We estimated median percentage population-level tuberculosis incidence rate reduction (IRR) in 2050 compared to a no new vaccine scenario. In all settings, results suggested vaccines preventing disease in M.tb-infected populations would have greatest impact by 2050 (10-year, 70% efficacy against disease, IRR 51%, 52%, and 54% in China, South Africa, and India, respectively). Vaccines preventing reinfection delivered lower potential impact (IRR 1, 12, and 17%). Intermediate impact was predicted for vaccines effective only in uninfected populations, if preventing infection (IRR 21, 37, and 50%) or disease (IRR 19, 36, and 51%), with greater impact in higher-transmission settings. Tuberculosis vaccines have the potential to deliver substantial population-level impact. For prioritizing impact by 2050, vaccine development should focus on preventing disease in M.tb-infected populations. Preventing infection or disease in uninfected populations may be useful in higher transmission settings. As vaccine impact depended on epidemiology, different development strategies may be required.

Roles of attitudes and injunctive norms in decisional conflict and disclosure following receipt of genome sequencing results

Social Science & Medicine
Volume 262 October 2020
https://www.sciencedirect.com/journal/social-science-and-medicine/vol/262/suppl/C

 

Research article Abstract only
Roles of attitudes and injunctive norms in decisional conflict and disclosure following receipt of genome sequencing results
Individuals who choose to obtain genetic information may learn that their genetic profile confers health risks to themselves or offspring. Individuals may react more negatively to this information when personal attitudes, perceived norms, and/or the decision to receive results conflict with one another.
Allecia E. Reid, Rebecca A. Ferrer, Sanjana Kadirvel, Barbara B. Biesecker, … William M.P. Klein
Article 113147

A systematic literature review of health consumer attitudes towards secondary use and sharing of health administrative and clinical trial data: a focus on privacy, trust, and transparency

Systematic Reviews
https://systematicreviewsjournal.biomedcentral.com/articles
[Accessed 10 Oct 2020]

 

A systematic literature review of health consumer attitudes towards secondary use and sharing of health administrative and clinical trial data: a focus on privacy, trust, and transparency
We aimed to synthesise data on issues related to stakeholder perceptions of privacy, trust, and transparency in use of secondary data. A systematic literature review of healthcare consumer attitudes towards th…
Authors: Elizabeth Hutchings, Max Loomes, Phyllis Butow and Frances M. Boyle
Citation: Systematic Reviews 2020 9:235
Content type: Research
Published on: 9 October 2020

An optimal typhoid conjugate vaccine coverage complemented with WASH is imperative for the control of antimicrobial resistance in Pakistan

Vaccine
Volume 38, Issue 45 Pages 6967-7182 (21 October 2020)
https://www.sciencedirect.com/journal/vaccine/vol/38/issue/45

 

Discussion No access
An optimal typhoid conjugate vaccine coverage complemented with WASH is imperative for the control of antimicrobial resistance in Pakistan
M. Imran Khan, Saher Aijaz, Farzeen Fatma Syed, Linda Kaljee
Pages 6969-6970

Integrating public health programs and research after the malaria vaccine implementation program (MVIP): Recommendations for next steps

Vaccine
Volume 38, Issue 45 Pages 6967-7182 (21 October 2020)
https://www.sciencedirect.com/journal/vaccine/vol/38/issue/45

 

Discussion Open access
Integrating public health programs and research after the malaria vaccine implementation program (MVIP): Recommendations for next steps
Rieke van der Graaf, Ruth Macklin, Annette Rid, Anant Bhan, … Johannes J.M. van Delden
Pages 6975-6978
Highlights
:: It is prudent to apply ethical norms for research involving humans to the WHO MVIP.
:: The MVIP might not meet the requirements of informed consent, independent ethical review, and social value.
:: WHO should make the MVIP protocol publicly available.
:: Independent ethical review should be conducted and fully informed consent obtained.
:: Communities should be engaged and alterable aspects of the MVIP should be altered.
Abstract
Background
In February 2020, international controversy arose about the ethical acceptability of the WHO Malaria Vaccine Implementation Program (MVIP). Whereas some have argued that this program must be seen as research that is not in line with international ethical standards, notably regarding informed consent and local ethical review, some WHO representatives consider the MVIP as a public health implementation program that need not adhere to these standards.
Methods
We performed a case analysis in light of the 2016 CIOMS International Ethical Guidelines for Health-related Research involving Humans.
Findings
We argue that the MVIP has a substantial research component, and that it is prudent to therefore apply ethical norms for research involving humans, such as the CIOMS guidelines. Accordingly, we agree that the ethical requirements of informed consent and independent ethical review have not been met. In addition, we are concerned that the study might not meet CIOMS’s social value requirement.
Recommendations
We urge WHO to release more details about the process that led to the MVIP program and make the MVIP protocol publicly available. The full protocol should be assessed by the relevant ethics committees, new and already enrolled parents should be informed about the uncertainties under investigation and given a real opportunity to consent or refuse (continued) participation, communities should be engaged, and aspects of MVIP that require alteration in light of ethical review should be altered, if possible. Furthermore, in order to improve good ethical practices, it is necessary to engage in international debate regarding the integration of research and public health programs. Procedurally, vaccine implementation programs that combine both prevention and research should involve the wider international ethics community and ensure participation of the target populations in setting the proper conditions for launching such programs.

Parental attitudes and decisions regarding MMR vaccination during an outbreak of measles among an undervaccinated Somali community in Minnesota

Vaccine
Volume 38, Issue 45 Pages 6967-7182 (21 October 2020)
https://www.sciencedirect.com/journal/vaccine/vol/38/issue/45

 

Short communication Abstract only
Parental attitudes and decisions regarding MMR vaccination during an outbreak of measles among an undervaccinated Somali community in Minnesota
Ben Christianson, Fatuma Sharif-Mohamed, Jennifer Heath, Margaret Roddy, … Cynthia Kenyon
Pages 6979-6984

Intention to participate in a COVID-19 vaccine clinical trial and to get vaccinated against COVID-19 in France during the pandemic

Vaccine
Volume 38, Issue 45 Pages 6967-7182 (21 October 2020)
https://www.sciencedirect.com/journal/vaccine/vol/38/issue/45

 

Research article Full text access
Intention to participate in a COVID-19 vaccine clinical trial and to get vaccinated against COVID-19 in France during the pandemic
Maëlle Detoc, Sébastien Bruel, Paul Frappe, Bernard Tardy, … Amandine Gagneux-Brunon
Pages 7002-7006

Influenza economic burden among potential target risk groups for immunization in South Africa, 2013–2015

Vaccine
Volume 38, Issue 45 Pages 6967-7182 (21 October 2020)
https://www.sciencedirect.com/journal/vaccine/vol/38/issue/45

 

Research article Abstract only
Influenza economic burden among potential target risk groups for immunization in South Africa, 2013–2015
Stefano Tempia, Jocelyn Moyes, Adam L. Cohen, Sibongile Walaza, … Cheryl Cohen
Pages 7007-7014

Maternal and paternal confidence in vaccine safety: Whose attitudes are predictive of children’s vaccination?

Vaccine
Volume 38, Issue 45 Pages 6967-7182 (21 October 2020)
https://www.sciencedirect.com/journal/vaccine/vol/38/issue/45

 

Research article Abstract only
Maternal and paternal confidence in vaccine safety: Whose attitudes are predictive of children’s vaccination?
Carol H.J. Lee, Nickola C. Overall, Chris G. Sibley
Pages 7057-7062

Rate of preventative vaccine use and vaccine beliefs among a commercially insured population

Vaccine
Volume 38, Issue 45 Pages 6967-7182 (21 October 2020)
https://www.sciencedirect.com/journal/vaccine/vol/38/issue/45

 

Research article Abstract only
Rate of preventative vaccine use and vaccine beliefs among a commercially insured population
Karri A. Bauer, Kelly Johnson, Judith J. Stephenson, Jay Visaria, … Laura A. Puzniak
Pages 7087-7093

The role of National Immunization Technical Advisory Groups (NITAG) in strengthening health system governance: Lessons from three middle-income countries—Argentina, Jordan, and South Africa (2017–2018)

Vaccine
Volume 38, Issue 45 Pages 6967-7182 (21 October 2020)
https://www.sciencedirect.com/journal/vaccine/vol/38/issue/45

 

Research article Abstract only
The role of National Immunization Technical Advisory Groups (NITAG) in strengthening health system governance: Lessons from three middle-income countries—Argentina, Jordan, and South Africa (2017–2018)
Maria S. Panero, Najwa Khuri-Bulos, Cristián Biscayart, Pablo Bonvehí, … Shabir A. Madhi
Pages 7118-7128

Impact of COVID-19 pandemic response on uptake of routine immunizations in Sindh, Pakistan: An analysis of provincial electronic immunization registry data

Vaccine
Volume 38, Issue 45 Pages 6967-7182 (21 October 2020)
https://www.sciencedirect.com/journal/vaccine/vol/38/issue/45

 

Research article Full text access
Impact of COVID-19 pandemic response on uptake of routine immunizations in Sindh, Pakistan: An analysis of provincial electronic immunization registry data
Subhash Chandir, Danya Arif Siddiqi, Mariam Mehmood, Hamidreza Setayesh, … Aamir Javed Khan
Pages 7146-7155

An Overview of the Development of New Vaccines for Tuberculosis

Vaccines — Open Access Journal
http://www.mdpi.com/journal/vaccines
(Accessed 10 Oct 2020)

 

Open Access Review
An Overview of the Development of New Vaccines for Tuberculosis
by E. Whitlow, A. S. Mustafa and S. N. M. Hanif
Vaccines 2020, 8(4), 586; https://doi.org/10.3390/vaccines8040586 – 05 Oct 2020
Viewed by 224
Abstract
Currently, there is only one licensed vaccine against tuberculosis (TB), the Bacillus Calmette–Guérin (BCG). Despite its protective efficacy against TB in children, BCG has failed to protect adults against pulmonary TB, lacks therapeutic value, and causes complications in immunocompromised individuals. Furthermore, it compromises

Use of Real-World Evidence to Support FDA Approval of Oncology Drugs

Value in Health
October 2020 Volume 23, Issue 10, p1281-1402
https://www.valueinhealthjournal.com/issue/S1098-3015(20)X0012-X

 

HEALTH POLICY ANALYSIS
Use of Real-World Evidence to Support FDA Approval of Oncology Drugs
Bruce A. Feinberg, Ajeet Gajra, Marjorie E. Zettler, Todd D. Phillips, Eli G. Phillips Jr., Jonathan K. Kish
p1358–1365
Published online: September 14, 2020
Highlights
:: In accordance with the 21st Century Cures Act directive, the Food and Drug Administration (FDA) is evaluating the potential for real-world evidence (RWE) to support the approval of supplementary indications or fulfill post-approval study requirements for drugs.
:: Our analysis found that significant precedent exists for the FDA’s acceptance of RWE (including data from electronic health records, claims, post-marketing safety reports, retrospective medical record reviews, and expanded access studies) to support oncology drug approvals, especially for rare or orphan indications.
:: The use of RWE to support drug approval is a viable strategy with the potential to provide clinically relevant information while reducing the time, cost, and patient burden associated with clinical trials.

Media/Policy Watch

Media/Policy Watch
This watch section is intended to alert readers to substantive news, analysis and opinion from the general media and selected think tanks and similar organizations on vaccines, immunization, global public health and related themes. Media Watch is not intended to be exhaustive, but indicative of themes and issues CVEP is actively tracking. This section will grow from an initial base of newspapers, magazines and blog sources, and is segregated from Journal Watch above which scans the peer-reviewed journal ecology.
We acknowledge the Western/Northern bias in this initial selection of titles and invite suggestions for expanded coverage. We are conservative in our outlook in adding news sources which largely report on primary content we are already covering above. Many electronic media sources have tiered, fee-based subscription models for access. We will provide full-text where content is published without restriction, but most publications require registration and some subscription level.

 

The Atlantic
http://www.theatlantic.com/magazine/
Accessed 10 Oct 2020
What Happens If the U.S. Withdraws From the W.H.O.? – How China Outsmarted the Trump Administration
While the U.S. is distracted, China is rewriting the rules of the global order.
Story by Anne Applebaum
November 2020 Issue
… American withdrawal from the WHO will have another impact: China’s influence will grow. And America will lose yet another battle in an ideological war that most of us don’t even know we are fighting. For more than a decade, while we’ve been distracted by other things, the Chinese government has made the gradual rewriting of international rules—all kinds of rules, in many realms, including commerce and politics—one of the central pillars of its foreign policy. At a Communist Party congress in 2017, Chinese President Xi Jinping openly declared this to be a “new era” of “great-power diplomacy with Chinese characteristics.” And in this new era—a time of the “great rejuvenation of the Chinese nation”—China is seeking to “take an active part in leading the reform of the global governance system.” Stated plainly, this is an attempt to rewrite the operating language of the international system so that it benefits autocracies instead of democracies….

 

BBC
http://www.bbc.co.uk/
Accessed 10 Oct 2020
Health
Measles in DR Congo: By air, boat and foot to deliver the vaccine
The health workers going to great lengths to deliver vital supplies in the fight against measles in DR Congo.
Published 5 Oct 2020

 

The Economist
http://www.economist.com/
Accessed 10 Oct 2020
Deliverance delayed
Pakistan and Afghanistan are the last countries fighting polio
Covid-19 has contributed to a resurgence in the poliovirus
Oct 10th 2020 edition

 

Financial Times
https://www.ft.com/
Accessed 10 Oct 2020
Coronavirus treatment
US should not approve vaccine based on UK trials, says Pelosi
…Nancy Pelosi has said that the US should not approve a Covid-19 vaccine based on data from British trials, amid fears that the Trump administration is planning to rush out an inoculation before…
October 9, 2020

Coronavirus treatment
China joins WHO vaccine initiative in diplomatic push
…China will join a World Health Organization initiative aimed at ensuring fair distribution of Covid-19 vaccines around the world as part of Beijing’s latest effort to steal a public relations march on…
October 9, 2020

Trade Secrets
Impending row over Covid vaccine patents at WTO
…provocative move at the WTO over intellectual property rights for Covid-19 vaccines and other treatments, while Tall Tales is about USTR Robert Lighthizer’s attempts to spin horrendous news as a victory. Our…
October 8, 2020

Special Report
Future of Logistics
Logisticians grapple to map out ‘cold chain’ for vaccine campaign
…While you are sleeping, swarms of Unicef logisticians around the world are busy mapping the world’s fridges. The logisticians are part of the organisation’s efforts to ensure that a Covid-19 vaccine…
October 8, 2020

Coronavirus treatment
AstraZeneca vaccine document shows limit of no-profit pledge
…AstraZeneca, which has promised not to profit from its Covid-19 vaccine “during the pandemic”, has the right to declare an end to the pandemic as soon as July 2021, according to an agreement with a…
October 7, 2020

Donald Trump
Trump accuses US drug regulator of ‘political hit job’ over Covid vaccine
…Drug Administration of making it more difficult to approve a vaccine ahead of the presidential election on November 3, after the agency passed tough new guidelines.“New FDA Rules make it more difficult…
October 7, 2020

Coronavirus:
Less than half UK population to receive coronavirus vaccine, says task force head | Free to read
…Less than half the UK population can expect to be vaccinated against coronavirus, the head of the government’s vaccine task force has said in an attempt to clear up the public’s “misguided” perception…
October 4, 2020
Top of Form
Bottom of Form

 

Forbes
http://www.forbes.com/
Accessed 10 Oct 2020
Oct 9, 2020
Report: White House Rejected CDC Mask Mandate On Commercial And Public Transportation
The White House has increasingly butted heads with the CDC in the past month.
By Matt Perez Forbes Staff

Oct 9, 2020
Bill Gates Lambastes Trump For Politicizing Science
Bill Gates criticized Donald Trump for politicizing science and outlined the plan for a return to normal.
By Will Jeakle Contributor

Oct 9, 2020
State Of Emergency Declared, Highest Ever Rates, As EU Orders Up To 400 Million Doses Of Vaccine
The EU has announced a deal to buy 200 million doses of vaccine–as Madrid declares state of emergency and France records highest ever rates.
By Alex Ledsom Senior Contributor

 

Foreign Affairs
http://www.foreignaffairs.com/
Accessed 10 Oct 2020
[No new, unique, relevant content]

 

Foreign Policy
http://foreignpolicy.com/
Accessed 10 Oct 2020
Security Brief
Foreign Aid Is Caught in the Crossfire of Trump’s Stimulus Battle
Aid groups fear that government inaction will fuel economic malaise, hunger, and disease in the developing world.
| October 8, 2020, 1:12 PM Jack Detsch, Robbie Gramer

 

The Guardian
http://www.guardiannews.com/
[No new, unique, relevant content]

 

New Yorker
http://www.newyorker.com/
Video Dept.
Anthony Fauci on the Coronavirus and the Prospects for a Vaccine
On the first night of the 2020 New Yorker Festival, the infectious-disease specialist spoke about COVID-19, superspreaders, and a possible vaccine.
By Rachel Riederer October 6, 2020

 

New York Times
http://www.nytimes.com/
Accessed 10 Oct 2020
Politics
Battered by Trump, the C.D.C.’s Director Faces Pressure to Speak Out
The agency prides itself on avoiding Washington partisanship. But the White House has successfully pushed the agency to revise guidelines on matters like school reopenings and church gatherings.
By Sheryl Gay Stolberg
PRINT EDITIONC.D.C.’s Director Is Challenged to ‘Stand Up to a Bully’|October 11, 2020, Page A14

Health
White House Blocked C.D.C. From Requiring Masks on Public Transportation
The order would have mandated that both passengers and employees wear face coverings on planes, trains, buses and subways and in airports, stations and depots.
By Sheila Kaplan
PRINT EDITIONC.D.C.’s Order for Masks On Transit Was Blocked|October 10, 2020, Page A6

 

Washington Post
https://www.washingtonpost.com/
Accessed 10 Oct 2020
Vaccine official who filed complaint against Trump administration resigns from NIH
One of the federal government’s top vaccine officials resigned from his role at the National Institutes of Health on Tuesday after accusing his superiors of politically motivated retaliation in response to his criticism of the Trump administration’s handling of the coronavirus pandemic.
Rick Bright, who formerly directed the Biomedical Advanced Research and Development Authority, was removed from his post in April and reassigned to a narrower role at NIH, where, he said in a whistleblower complaint, his work was “thwarted by political considerations that continue to harm public health and safety.” The complaint accuses Department of Health and Human Services leaders of giving Bright a less prestigious job because he pushed back against President Trump’s lofty claims about hydroxychloroquine’s potential as a covid-19 treatment…
Teo Armus, Jennifer Hassan, Adam Taylor, Lateshia Beachum, Paulina Villegas, Hannah Denham and Reis Thebault · National · Oct 6, 2020

Think Tanks et al

Think Tanks et al

Brookings
http://www.brookings.edu/
Accessed 10 Oct 2020
[No new relevant content]
 
 
Center for Global Development [to 10 Oct 2020]
http://www.cgdev.org/page/press-center
[No new relevant content]

 

Chatham House [to 10 Oct 2020]
https://www.chathamhouse.org/
Webinar:
Webinar: Living with COVID-19: Opportunism and International Security
14 October 2020 – 11:00am to 12:00pm
(London, GMT)

 

CSIS
https://www.csis.org/
Accessed 10 Oct 2020
Commentary
Getting More Visibility into Medical Supply Chains
October 6, 2020
Unprecedented demand shocks for medical products important for treating Covid-19 hit the U.S. market in the spring of 2020, resulting in severe shortages and transportation bottlenecks. Suddenly, there was an expanded awareness of the complex international nature of supply chains for many essential products, which engendered intense concern among policymakers and the public. As a result, there is now great interest in what has been, over time, a steadily growing web of far-flung sourcing and manufacturing relationships based on specialization and production efficiencies. There is a surge of political momentum for government action to ensure that U.S. citizens are safe should another pandemic occur. As policy prescriptions are being debated, building more resilience and security into supply chains is the agreed goal…

 

Council on Foreign Relations
http://www.cfr.org/
Accessed 10 Oct 2020
Coronavirus
The Path to a COVID-19 Vaccine
How is a vaccine developed? Can a vaccine end the COVID-19 pandemic? Senior Fellow Tom Bollyky answers pressing questions about the search for a coronavirus vaccine.
by Thamine Nayeem October 6, 2020

 

Kaiser Family Foundation
https://www.kff.org/search/?post_type=press-release
Accessed 10 Oct 2020
[No new relevant content]

Vaccines and Global Health: The Week in Review :: 3 October 2020

Vaccines and Global Health: The Week in Review is a weekly digest  summarizing news, events, announcements, peer-reviewed articles and research in the global vaccine ethics and policy space. Content is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage. You are viewing the blog version of our weekly digest, typically comprised of between 30 and 40 posts below all dated with the current issue date

.– Request an Email Summary: Vaccines and Global Health : The Week in Review is published as a single email summary, scheduled for release each Saturday evening before midnight (EDT in the U.S.). If you would like to receive the email version, please send your request to david.r.curry@centerforvaccineethicsandpolicy.org.

– pdf version A pdf of the current issue is available here: 

– blog edition: comprised of the approx. 35+ entries posted below.

– Twitter:  Readers can also follow developments on twitter: @vaxethicspolicy.
.
– Links:  We endeavor to test each link as we incorporate it into any post, but recognize that some links may become “stale” as publications and websites reorganize content over time. We apologize in advance for any links that may not be operative. We believe the contextual information in a given post should allow retrieval, but please contact us as above for assistance if necessary.

Support this knowledge-sharing service: Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click here to donate and thank you in advance for your contribution.

.
David R. Curry, MS
Executive Director
Center for Vaccine Ethics and Policy